E3 ubiquitin ligase BCA2 promotes breast cancer stemness by up-regulation of SOX9 by LPS
- Int J Biol Sci. 2024 Apr 29;20(7):2686-2697. doi: 10.7150/ijbs.92338.
- 1. Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, 650201, China.
- 2. Kunming College of Life Sciences, University of Chinese Academy of Sciences, Kunming, Yunnan, China.
- 3. The Third Affiliated Hospital, Kunming Medical University, Kunming, 650118, China.
- 4. Department of Pathology, Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, China.
- 5. The First Affiliated Hospital, Kunming Medical University, Kunming, 650032, China.
- 6. Academy of Biomedical Engineering, Kunming Medical University, Kunming, 650500, China.
Triple-Negative Breast Cancer (TNBC) is the most malignant subtype of Breast Cancer. Breast Cancer Stem Cells (BCSCs) are believed to play a crucial role in the carcinogenesis, therapy resistance, and metastasis of TNBC. It is well known that inflammation promotes stemness. Several studies have identified breast cancer-associated gene 2 (BCA2) as a potential risk factor for Breast Cancer incidence and prognosis. However, whether and how BCA2 promotes BCSCs has not been elucidated. Here, we demonstrated that BCA2 specifically promotes lipopolysaccharide (LPS)-induced BCSCs through LPS induced SOX9 expression. BCA2 enhances the interaction between myeloid differentiation primary response protein 88 (MyD88) and Toll-like Receptor 4 (TLR4) and inhibits the interaction of MyD88 with Deubiquitinase OTUD4 in the LPS-mediated NF-κB signaling pathway. And SOX9, an NF-κB target gene, mediates BCA2's pro-stemness function in TNBC. Our findings provide new insights into the molecular mechanisms by which BCA2 promotes Breast Cancer and potential therapeutic targets for the treatment of Breast Cancer.
-
Cat. No.Product NameCategory/Application